Purging the latent reservoir of HIV-1
in resting CD4+ T cells by HDAC inhibitors inhibitors
is under active clinical investigation.
Use of well-tolerated and selective
HDAC inhibitors for HIV-1 purging
should be tested in vitro and provide a
rationale for clinical studies in aviremic
HIV-1 patients on antiretroviral therapy.